Back to CGC
CGC: Canopy Growth - Growth vs. Losses
$CGCNEUTRALDrug Manufacturers—Specialty & Generic

CGC: Canopy Growth - Growth vs. Losses

Canopy Growth reported 22% Q2 revenue growth led by a surge in international sales, but the company posted an EPS miss on November 6, 2026 and remains unprofitable. This report analyzes the setup, balance sheet health, valuation disconnects, and the key catalysts and risks heading into the coming quarters.

November 7, 202612 min read
Current Price
$0.65
-3.58%
Analyst Rating
Hold
Price Target
$14.47
2121.0% upside
P/E Ratio
-1.38

Executive Summary

Investment Thesis: Canopy Growth ($CGC) is showing topline recovery, with fiscal Q2 2027 revenue rising roughly 22% and international cannabis sales more than doubling. The company still reports recurring net losses and negative profitability metrics, and the share price is trading near its 52-week low which reflects investor caution. Balance sheet liquidity looks manageable for now, but operating cashflow remains negative and execution will determine whether revenue growth translates into sustained profitability.

Current Price: $0.6515 as of Friday, November 6 | Key Metric: Market Cap $0.28B | Stance: NEUTRAL

Company Overview

Canopy Growth Corporation operates in the legal cannabis market across multiple jurisdictions, producing and selling adult-use and medical cannabis products. The company is vertically integrated with cultivation, processing, brand development, and international distribution capabilities.

Key Products & Competitive Position

  • Core Business: Cultivation and sale of cannabis flower, pre-rolls, extracts, edibles and related consumer brands, plus international distribution and selected research initiatives.
  • Key Products: Branded consumer cannabis products for adult-use and medical programs, bulk and wholesale supply to international markets, and ancillary product lines.
  • Competitive Moat: Established brand portfolio and scale in certain markets, intellectual property around product formulations, and an international distribution footprint that has driven recent top-line growth.

Recent Developments

On November 6, 2026 Canopy Growth reported fiscal Q2 2027 results showing 22% net revenue growth with international cannabis sales up roughly 141%. Management reiterated progress toward profitability targets and positive adjusted EBITDA objectives in prior commentary. The company hosted an earnings call the same day where executives outlined cost optimization and international expansion updates.

Financial Snapshot

Market Cap$0.28B
P/E Ratio-1.38
52-Week Range$0.5809 - $2.38
Dividend Yield0.0%
EPS (TTM)$-0.56
ROE-29.85%

Revenue & Earnings Trends

Revenue has shown signs of stabilization and modest growth. Fiscal year revenue moved from roughly $269M in 2025 to about $285M in 2026, representing low double digit growth year over year. The November quarter release highlighted a 22% sequential or year over year increase in fiscal Q2 2027 driven by international channel growth. Gross margins are positive at about 28.5% on reported data, but operating margins remain negative near -21.7%. Net losses are persistent, with TTM EPS at -$0.56.

Balance Sheet Highlights

Liquidity metrics look acceptable for a company in restructuring mode. As of the latest public filings there is roughly $338M in cash versus reported total debt near $277M. That gives a net cash-like position if you ignore operating liabilities, and the current ratio is healthy at about 3.04 which suggests short-term obligations are covered. However operating cashflow has been negative recently and free cash flow has been small historically, so sustaining the cash runway depends on continued revenue growth and cost control.

Valuation Analysis

Current Valuation Metrics

Forward P/EN/Avs Industry: N/A
PEG RatioN/AGrowth-adjusted
EV/EBITDAN/Avs Historical: N/A
P/S Ratio~0.98vs Peers: Lower

Historical Comparison

Over the past five years $CGC traded materially higher during the earlier legalization optimism phase, then fell sharply as industry economics and oversupply pressured margins. The current share price near $0.65 is well below the 52-week high of $2.38, roughly 73% below that high. Relative to historical revenue multiples the stock now trades at a low P/S multiple under 1, reflecting market skepticism about sustainable profits and industry consolidation risks.

Fair Value Estimate

A simple, conservative view that adjusts for continued losses suggests a wide intrinsic value range. If the company converts current revenue growth into positive adjusted EBITDA within 2 to 4 quarters and maintains gross margins above 25%, an enterprise multiple in a recovery scenario could imply a per share valuation in the low single digits. Analysts' mean targets are much higher which implies either a very aggressive recovery scenario or outlier calculations. The data suggests fair value is highly sensitive to timing of profitability and international execution.

Competitive Landscape

Market Position

Market Share: Small single-digit share within global cannabis markets | Ranking: One of the larger legacy Canadian producers but not market dominant globally

Key Competitors

Cronos Group (CRON)Large Canadian peer with wide retail distribution and international operations
Tilray Brands (TLRY)US-listed cannabis company with strong brand and US market exposure
$CGC.TOCanopy's TSX listing for Canadian investor comparables

Competitive Advantages

  • Moat 1: Brand recognition in key markets and a diversified product lineup.
  • Moat 2: Scale in cultivation and production that can drive unit cost improvements if utilization rises.
  • Moat 3: International distribution gains that have shown early traction and contributed to recent revenue growth.

Earnings Track Record

Last 4 Quarters: 2 beats / 2 misses

Recent Earnings History

Q2 2027 (11/06/2026)$-0.07 vs $-0.02 estMISS
Q1 2027 (08/07/2026)$-0.02 vs $-0.04 estBEAT
Recent prior quarterNegative EPS vs small losses expectedMISS
Earlier quarterSmall loss better than estimateBEAT

Guidance Trend

Management commentary at the Q2 earnings call emphasized revenue momentum in international channels and reiterated focus on reaching adjusted EBITDA positivity. Official GAAP guidance remains limited given industry uncertainty, but executives pointed to cost reductions and portfolio rationalization as the mechanism to bridge to profitability. Analysts have been cautious and consensus remains a Hold with two Buy voice notes among eight contributors.

Analyst Sentiment

Consensus Rating: Hold

Strong Buy: 0 Buy: 2 Hold: 6 Sell: 0

Price Targets

  • Low: $8
  • Mean: $14.47 (+2121% upside)
  • High: $27.85

Recent Analyst Actions

Most recent rating activity has been muted, with a prevailing Hold consensus. The wide dispersion of price targets reflects differing assumptions on timing to profitability and on the value of international growth. Analysts note that targets in the mid-teens require substantial margin improvement and successful international rollouts.

Recent News & Catalysts

Key Developments

  • Q2 2027 Earnings Call (11/6/2026): Management discussed the quarter and flagged international sales more than doubling, a 22% increase in net revenue, and ongoing cost rationalization steps.
  • Earnings Miss: Reported EPS $-0.07 vs consensus $-0.02, which disappointed some investors and analysts and pressured the share price heading into the long weekend.
  • Operational Moves: Company statements emphasize portfolio optimization and focus on adjusted EBITDA improvement over the coming quarters.

Upcoming Catalysts

Next Earnings: Next quarterly report not yet scheduled publicly | Key Events: Updates on international distribution rollout, adjusted EBITDA progress, and operating cashflow trends.

Technical Outlook

Current Price: $0.6515 vs 52-Week High: $2.38 (-73% from high)

Trend Analysis

The technical pattern is bearish on multiple timeframes with the stock trading near its 52-week low and below common longer-term moving averages. Volume spiked around earnings and major news events which signals continued investor interest but also high volatility. Momentum indicators indicate downside pressure, while short-term oversold readings could produce intermittent bounces.

Key Levels

  • Resistance: $1.00, $1.75
  • Support: $0.5809 (52-week low), $0.50

Bull vs Bear Case

Bull Case

  • Catalyst 1: Continued international growth could materially lift top-line and improve gross margins.
  • Catalyst 2: Cost rationalization and higher facility utilization could drive adjusted EBITDA to positive territory within a few quarters.
  • Catalyst 3: Current market pricing already discounts a lot of downside which makes upside from execution significant if management delivers sustained profitability.

Bull Target: $14.47 (analyst mean, +2121%)

Bear Case

  • Risk 1: Persisting net losses with negative operating cashflow could erode liquidity despite a currently strong current ratio.
  • Risk 2: Regulatory, pricing and competitive pressures could limit international expansion or compress margins further.
  • Risk 3: High beta and low absolute price mean share price could stay depressed or fall further during risk-off periods.

Bear Target: $0.40 (-39%)

Risks to Consider

  • Valuation Risk: Wide analyst target dispersion implies valuation is highly sensitive to small changes in profit timing and margin assumptions.
  • Competitive Risk: Competing legacy producers and new entrants may pressure pricing and shelf space in key retail channels.
  • Macro Risk: Higher interest rates and risk-off market sentiment may reduce capital availability for cannabis companies and compress multiples further.
  • Execution Risk: Conversion of international revenue into sustainable profits requires supply chain, regulatory and retail execution across jurisdictions.

Bottom Line

Investment Verdict: NEUTRAL

Canopy Growth is showing encouraging top-line momentum in international markets while continuing to face profitability and cashflow challenges. Analysts are split and consensus is Hold. The stock's current valuation reflects significant uncertainty and a wide range of potential outcomes depending on execution and industry dynamics.

Action Items for Investors

  • Long-term investors: Monitor sustained adjusted EBITDA improvement, cashflow trends, and execution of international expansion before altering exposure.
  • Short-term traders: Watch support at $0.5809 and intraday liquidity around earnings, and be prepared for high volatility on news flow.
  • Risk management: Consider position sizing that accounts for high beta, set stop levels and track quarterly cash burn versus cash on hand.

What to Watch This Week

  • Follow-up analyst notes reacting to the November 6, 2026 Q2 release and any updated guidance points.
  • Operational updates on international distribution or retail agreements that could confirm revenue gains sustain.
  • Cashflow and adjusted EBITDA commentary in subsequent investor communications.

Are you comfortable with a high-beta equity that trades near multi-year lows and depends on execution to realize the upside in analyst scenarios? If not, watching operational proof points before increasing exposure can reduce headline risk.

Note: This report is for informational purposes only. It does not provide personalized investment advice or a recommendation to buy, sell, or hold $CGC. Analysts note the company's progress and the risks highlighted here, and data suggests outcomes will be driven by execution on profitability and international expansion.

Share this report

Share this article

Spread the word on social media

Think CGC will outperform? Prove it.

Free practice contests — earn Alpha Coins
Enter a Contest

Disclaimer: StockAlpha.ai content is for informational and educational purposes only. It is not personalized investment advice. Sentiment ratings and market analysis reflect data-driven observations, not buy, sell, or hold recommendations. Always consult a qualified financial advisor before making investment decisions. Past performance does not guarantee future results.

Spotted something wrong? Report an error.